Article Text

other Versions

PDF
Characteristics of KIT-negative gastrointestinal stromal tumors and diagnostic utility of protein kinase C theta immunostaining
  1. Hee Eun Lee (ichcream{at}empal.com)
  1. Department of Pathology, Seoul National University College of Medicine, Korea, Republic of
    1. Min A Kim (kmamd{at}hanmail.net)
    1. Department of Pathology, Seoul National University College of Medicine, Korea, Republic of
      1. Hye Seung Lee (mw9195{at}hanmail.net)
      1. Department of Pathology, Seoul National University Bundang Hospital, Korea, Republic of
        1. Byung Lan Lee (dslanat{at}snu.ac.kr)
        1. Cancer Research Institute, Seoul National University College of Medicine, Korea, Republic of
          1. Woo Ho Kim (array123{at}freechal.com)
          1. Department of Pathology, Seoul National University College of Medicine, Korea, Republic of

            Abstract

            AIMS: The present study aimed to characterise KIT-negative gastrointestinal stromal tumor (GIST) clinically, pathologically, immunohistochemically, and genetically and to establish the usefulness of protein kinase C theta (PKCθ as a diagnostic marker in KIT-negative GIST.

            METHODS: A total of 252 consecutive cases of GIST were evaluated for clinicopathologic characteristics and immunostained for various antibodies. The mutational analyses of KIT and platelet-derived growth factor receptor α (PDGFRA) were also performed in 62 cases.

            RESULTS: Twenty (7.9%) GISTs showed negative immunostaining for KIT. KIT-negative GISTs were more likely to originate from omentum or peritoneum, have an epithelioid histology, and be classified as high risk. The overall survival rate of patients with KIT-negative GISTs (five-year survival rate, 68.7 ±10.7%) was lower than that of patients with KIT-positive GISTs (five-year survival rate, 79.9 ±3.0%) (P = 0.042, log-rank test), and it was found that negative KIT expression was an independent prognostic factor in multivariate Cox regression analysis when the risk of aggressive behavior and the status of imatinib treatment were adopted as covariates. KIT-negative GISTs also showed lower expression rates of CD34, Bcl-2, and PKCθ than KIT-positive GISTs, and mutational analysis revealed that 30% of KIT-negative GISTs harbored a PDGFRA exon 18 mutation. Immunostaining on PKCθ showed that 93.9% of all GISTs expressed PKCθ protein. However, 21.9% of 64 mesenchymal tumors other than GIST also showed positivity on PKCθ

            CONCLUSIONS: KIT-negative GISTs had characteristics that differ from those of KIT-positive GISTs, and negative KIT expression was an independent prognostic indicator for overall survival of patients. Although PKCθ is a sensitive diagnostic marker for GIST, its usefulness is limited because of low sensitivity and low specificity in KIT-negative GISTs.

            Statistics from Altmetric.com

            Request permissions

            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.